ReviewCurrent oncology reports2019
Evidence-Based Practice: Temozolomide Beyond Glioblastoma.
Review in Current oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 56 citations in OpenAlex.
- Development of AGT-7: An InnovativePharmaceuticals (Basel, Switzerland) · 2025Article
- Recent advances in immunotherapy for gliomas: overcoming barriers and advancing precision strategies.Frontiers in immunology · 2025Review
- Stemness subtypes in lower-grade glioma with prognostic biomarkers, tumor microenvironment, and treatment response.Scientific reports · 2024Article
- Complement and coagulation cascades are associated with prognosis and the immune microenvironment of lower-grade glioma.Translational cancer research · 2024Article
- Decoding Diffuse Midline Gliomas: A Comprehensive Review of Pathogenesis, Diagnosis and Treatment.Cancers · 2023Review
- Extensive Leptomeningeal Spreading of Ependymoma in an Adult: Case Report and Literature Review.Brain tumor research and treatment · 2023Article
- Drug-Loaded Lipid Magnetic Nanoparticles for Combined Local Hyperthermia and Chemotherapy against Glioblastoma Multiforme.ACS nano · 2023Article
- Radiotherapy and radio-sensitization in H3CNS neuroscience & therapeutics · 2023Review
- Glucosylceramide Synthase Inhibitors Induce Ceramide Accumulation and Sensitize H3K27 Mutant Diffuse Midline Glioma to Irradiation.International journal of molecular sciences · 2023Article
- Targeting IGF2BP3 in Cancer.International journal of molecular sciences · 2023Review
- Rare Neuronal, Glial and Glioneuronal Tumours in Adults.Cancers · 2023Review
- Lipid metabolism-related gene signature predicts prognosis and depicts tumor microenvironment immune landscape in gliomas.Frontiers in immunology · 2023Article
- Network pharmacology and experimental verification reveal the mechanism of safranal against glioblastoma (GBM).Frontiers in oncology · 2023Article
- Identification and verification of the temozolomide resistance feature gene DACH1 in gliomas.Frontiers in oncology · 2023Article
- Article
- New Directions in the Therapy of Glioblastoma.Cancers · 2022Review
- Neoantigen Vaccines; Clinical Trials, Classes, Indications, Adjuvants and Combinatorial Treatments.Cancers · 2022Review
- Rewired Metabolism of Amino Acids and Its Roles in Glioma Pathology.Metabolites · 2022Review
- SU4312 Represses Glioma Progression by Inhibiting YAP and Inducing Sensitization to the Effect of Temozolomide.Journal of clinical medicine · 2022Article
- Therapeutic Options in Neuro-Oncology.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTemozolomide is a first-line treatment for newly diagnosed glioblastoma. In this review, we will examine the use of temozolomide in other contexts for treating gliomas, including recurrent glioblastoma, glioblastoma in the elderly, diffuse low- and high-grade gliomas, non-diffuse gliomas, diffuse intrinsic pontine glioma (DIPG), ependymoma, pilocytic astrocytoma, and pleomorphic xanthoastrocytoma. RECENT
findingsTemozolomide improved survival in older patients with glioblastoma, anaplastic gliomas regardless of 1p/19q deletion status, and progressive ependymomas. Temozolomide afforded less toxicity and comparable efficacy to radiation in high-risk low-grade gliomas and to platinum-based chemotherapy in pediatric high-grade gliomas. The success of temozolomide in promoting survival has expanded beyond glioblastoma to benefit patients with non-glioblastoma tumors. Identifying practical biomarkers for predicting temozolomide susceptibility, and establishing complementary agents for chemosensitizing tumors to temozolomide, will be key next steps for future success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.